AVBP
NASDAQ · Biotechnology
Arrivent Biopharma Inc
$13.49
+0.47 (+3.61%)
Open$13.39
Previous Close$13.02
Day High$13.57
Day Low$12.47
52W High$35.83
52W Low$11.36
Volume—
Avg Volume1.91M
Market Cap603.03M
P/E Ratio—
EPS$-3.67
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+89.8% upside
Current
$13.49
$13.49
Target
$25.60
$25.60
$15.99
$25.60 avg
$32.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 217.05M | 207.22M | 172.47M |
| Net Income | -33,899,494 | -32,015,874 | -32,580,881 |
| Profit Margin | -15.6% | -15.5% | -18.9% |
| EBITDA | -52,835,285 | -48,435,254 | -38,009,184 |
| Free Cash Flow | -36,657,940 | -37,197,569 | -30,385,570 |
| Rev Growth | +1.9% | +19.8% | +13.5% |
| Debt/Equity | 0.28 | 0.20 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |